[go: up one dir, main page]

PA8578501A1 - Forma de dosificacion una vez al dia de pramipexol - Google Patents

Forma de dosificacion una vez al dia de pramipexol

Info

Publication number
PA8578501A1
PA8578501A1 PA20038578501A PA8578501A PA8578501A1 PA 8578501 A1 PA8578501 A1 PA 8578501A1 PA 20038578501 A PA20038578501 A PA 20038578501A PA 8578501 A PA8578501 A PA 8578501A PA 8578501 A1 PA8578501 A1 PA 8578501A1
Authority
PA
Panama
Prior art keywords
pramipexol
hours
approximately
average
absorption
Prior art date
Application number
PA20038578501A
Other languages
English (en)
Inventor
Ernest J Lee
Gerard M Bredael
John R Baldwin
Steven R Cox
Mark J Heintz
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31192088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8578501(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PA8578501A1 publication Critical patent/PA8578501A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA ADMINISTRABLE POR VIA ORAL COMPRENDE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE PRAMIPEXOL O DE UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y AL MENOS UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE, PRESENTANDO DICHA COMPOSICION AL MENOS UNO DE LOS PERFILES SIGUIENTES: (A) UN PERFIL DE LIBERACION IN VITRO DONDE, COMO PROMEDIO, NO MAS DE APROXIMADAMENTE UN 20% DEL PRAMIPEXOL SE DISUELVE DENTRO DE UN PERIODO DE 2 HORAS DESPUES DE PONER LA COMPOSICION EN UNA PRUEBA DE DISOLUCION ESTANDAR; Y (B) UN PERFIL DE ABSORCION DE PRAMIPEXOL IN VIVO DESPUES DE LA ADMINISTRACION DE UNA SOLA DOSIS A SERES HUMANOS ADULTOS SANOS DONDE EL TIEMPO PARA ALCANZAR UNA MEDIA DE UN 20% DE ABSORCION ES SUPERIOR A APROXIMADAMENTE 2 HORAS Y/O EL TIEMPO PARA ALCANZAR UNA MEDIA DE UN 40% DE ABSORCION ES SUPERIOR A APROXIMADAMENTE 4 HORAS. LA COMPOSICION ES UTIL PARA LA ADMINISTRACION POR VIA ORAL, NO MAS DE UNA VEZ AL DIA, A UN PACIENTE QUE TENGA UNA ENFERMEDAD O UN TRASTORNO PARA EL CUAL ESTA INDICADO UN AGONISTA DE LOS RECEPTORES DE LA DOPAMINA.
PA20038578501A 2002-07-25 2003-07-24 Forma de dosificacion una vez al dia de pramipexol PA8578501A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39842702P 2002-07-25 2002-07-25
US39844702P 2002-07-25 2002-07-25
US47951403P 2003-06-18 2003-06-18

Publications (1)

Publication Number Publication Date
PA8578501A1 true PA8578501A1 (es) 2005-02-04

Family

ID=31192088

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038578501A PA8578501A1 (es) 2002-07-25 2003-07-24 Forma de dosificacion una vez al dia de pramipexol

Country Status (40)

Country Link
US (2) US8679533B2 (es)
EP (2) EP2289514B9 (es)
JP (1) JP4607584B2 (es)
KR (2) KR101066374B1 (es)
CN (1) CN1671381B (es)
AP (1) AP2223A (es)
AR (1) AR040682A1 (es)
AU (1) AU2003256921B2 (es)
BR (1) BR0312948A (es)
CA (1) CA2493629C (es)
CU (1) CU23468B7 (es)
CY (2) CY1114263T1 (es)
DE (1) DE20321906U1 (es)
DK (2) DK1536792T3 (es)
EA (1) EA017595B1 (es)
EC (1) ECSP055569A (es)
ES (2) ES2421787T3 (es)
GE (1) GEP20074047B (es)
HK (1) HK1078007A1 (es)
HR (1) HRP20041234B1 (es)
IL (1) IL166076A0 (es)
IS (1) IS7613A (es)
MA (1) MA27372A1 (es)
ME (1) ME00347B (es)
MX (1) MXPA05000980A (es)
MY (1) MY142204A (es)
NO (1) NO20050481L (es)
NZ (1) NZ562681A (es)
OA (1) OA12889A (es)
PA (1) PA8578501A1 (es)
PE (1) PE20040134A1 (es)
PL (1) PL375444A1 (es)
PT (2) PT1536792E (es)
RS (1) RS52764B (es)
SG (1) SG177011A1 (es)
SI (2) SI2289514T1 (es)
TW (1) TWI351955B (es)
UY (1) UY27913A1 (es)
WO (1) WO2004010999A1 (es)
ZA (1) ZA200500015B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US7365086B2 (en) * 2003-07-25 2008-04-29 Synthon Ip Inc. Pramipexole acid addition salts
PT1781260E (pt) * 2004-08-13 2010-12-20 Boehringer Ingelheim Int Formulação em comprimido de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável, um método para a preparação do mesmo e sua utilização
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
KR20070058540A (ko) * 2004-10-01 2007-06-08 니폰 조키 세야쿠 가부시키가이샤 고형 의약제제
WO2006046256A1 (en) * 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
CA2652251A1 (en) * 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods for using the same
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2129382A4 (en) 2007-02-21 2011-01-19 Univ Michigan COMPOSITIONS AND METHODS FOR HEART MUSCLE PREVENTION
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
EP2167080A1 (en) * 2007-05-25 2010-03-31 Boehringer Ingelheim International GmbH Pharmaceutical formulation comprising pramipexole
WO2008150741A1 (en) * 2007-06-04 2008-12-11 Drugtech Corporation Controlled release dopamine agonist compositions
EP2291178A4 (en) * 2008-06-09 2013-07-24 Supernus Pharmaceuticals Inc PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE
EP2334185A4 (en) 2008-08-19 2011-09-21 Knopp Neurosciences Inc COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
AU2010234244A1 (en) * 2009-04-09 2011-10-13 Purdue Pharma Once-daily oral IR/CR pramipexole formulation
MX2012000096A (es) * 2009-07-02 2012-04-02 Supernus Pharmaceuticals Inc Un metodo de tratamiento de un trastorno neurologico.
WO2011037976A2 (en) * 2009-09-22 2011-03-31 Dr. Reddy's Laboratories Limited Pramipexole pharmaceutical formulations
WO2011086182A2 (en) * 2010-01-18 2011-07-21 Synthon Bv Pramipexole extended release tablets
TR201001862A1 (tr) * 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
US20130209553A1 (en) 2010-04-15 2013-08-15 Cadila Healthcare Limited Extended release pharmaceutical compositions of pramipexole
WO2011148243A1 (en) 2010-05-24 2011-12-01 Lupin Limited Extended release formulation of pramipexole
CN102670550A (zh) * 2011-03-14 2012-09-19 北京天衡药物研究院 盐酸普拉克索渗透泵型控释片
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
CN102406626B (zh) * 2011-12-02 2013-08-28 深圳海王药业有限公司 盐酸普拉克索缓释片剂及其制备方法
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (de) 2012-11-15 2014-05-21 Aristo Pharma GmbH Pramipexol-Retardtablettenformulierung
CN103058953B (zh) * 2012-11-22 2015-03-25 刘炜 用于治疗神经疾病的四氢苯并噻唑衍生物
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
HUE054185T2 (hu) 2013-07-12 2021-08-30 Knopp Biosciences Llc Eozinofilek és/vagy bazofilek megemelkedett szintjének kezelése
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
CN104606162B (zh) * 2015-01-07 2017-03-29 海南康虹医药科技开发有限公司 一种盐酸普拉克索缓释制剂及其制备方法
CN104784155B (zh) * 2015-05-15 2018-02-23 中国药科大学 一种盐酸普拉克索组合微丸胶囊及其制备方法
CN105030721B (zh) * 2015-08-30 2018-05-04 南京康川济医药科技有限公司 一种含有盐酸普拉克索的口服固体组合物
EP3522843B1 (en) * 2016-10-07 2022-09-21 Transwell Biotech Co., Ltd. Pramipexole transdermal delivery system and uses thereof
CN110402304A (zh) * 2016-12-21 2019-11-01 哈索赫伯特施密特有限两合公司 用于酸洗合成材料的酸洗液
AU2018258117A1 (en) * 2017-04-24 2019-12-12 Chase Therapeutics Corporation Compositions and method for treating depression
CN111212640A (zh) * 2017-08-17 2020-05-29 顾自强 单胺抗帕金森药物的双羟萘酸盐、其制备方法及其用途

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
NL265428A (es) 1960-06-06
US3458622A (en) 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja) * 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4666612A (en) 1986-03-17 1987-05-19 Kerr-Mcgee Chemical Corporation Method for recovering a wood preservative from waste sludges
US4772473A (en) 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4709712A (en) * 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4789549A (en) 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4859470A (en) 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
GB8828020D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
FR2653337B1 (fr) 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
EP0447168A3 (en) 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5656296A (en) 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5661171A (en) 1992-07-02 1997-08-26 Oramed, Inc. Controlled release pilocarpine delivery system
ES2179829T3 (es) 1992-09-18 2003-02-01 Yamanouchi Pharma Co Ltd Preparacion de hidrogel de liberacion prolongada.
DE4241013A1 (de) 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5650420A (en) 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
CA2232152C (en) 1995-12-27 2007-02-06 Janssen Pharmaceutica N.V. Bioadhesive solid dosage form
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
JPH1017497A (ja) 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
AU729529B2 (en) * 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
ATE322892T1 (de) 1997-07-02 2006-04-15 Euro Celtique Sa Stabilisierte tramadol formulierungen mit verzögerter freisetzung
CA2211778A1 (en) 1997-08-14 1999-02-14 Francois Carriere Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
NZ503464A (en) 1997-09-29 2002-05-31 Inhale Therapeutic Syst Perforated microparticles containing a bioactive agent for pulmonary delivery
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020054911A1 (en) 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
GB9802201D0 (en) 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
NZ505807A (en) * 1998-03-11 2003-01-31 Smithkline Beecham Corp Controlled release oral dosage form containing [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride; useful for the treatment or prophylaxis of dementia
WO1999059563A2 (en) 1998-05-15 1999-11-25 Pharmacia & Upjohn Company Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CN1208090C (zh) 1999-03-31 2005-06-29 詹森药业有限公司 在控制释放制剂中的预胶凝淀粉
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
CA2416233A1 (en) 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease
GB9923045D0 (en) 1999-09-29 1999-12-01 Novartis Ag New oral formulations
WO2001022820A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
WO2001028516A2 (en) 1999-10-19 2001-04-26 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating cns-mediated disorders
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PL355391A1 (en) 1999-12-22 2004-04-19 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
CA2332691C (en) 2000-01-27 2007-11-27 The York Group, Inc. Death care merchandising system
OA12215A (en) 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6277875B1 (en) 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
CA2418915A1 (en) 2000-08-08 2002-02-14 Teva Pharmaceutical Industries Ltd. Stable pergolide mesylate and process for making same
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
DE60237372D1 (de) 2001-07-04 2010-09-30 Sun Pharma Advanced Res Co Ltd Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
FR2827872A1 (fr) 2001-07-30 2003-01-31 Roussy Inst Gustave Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire
US20030032661A1 (en) 2001-08-02 2003-02-13 Boehringer Ingelheim Pharma Kg Pramipexole as an anticonvulsant
GB0125088D0 (en) 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
JP2005516020A (ja) * 2001-12-20 2005-06-02 ファルマシア・コーポレーション ゼロ次持続放出剤形およびその製造方法
CN101410091A (zh) 2002-01-04 2009-04-15 Ivax研究公司 用于持续释放格列吡嗪的药物递送系统
KR20040091100A (ko) 2002-03-04 2004-10-27 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 운반체 펩타이드를 함유하는 서방형 의약 조성물
EP1639997A1 (en) 2002-04-05 2006-03-29 Euro-Celtique S.A. Matrix for sustained, invariant and independant release of active compounds
IL164438A0 (en) 2002-04-15 2005-12-18 Adams Lab Inc Sustaubed release of guaifenesin combination drugs
US20030215498A1 (en) 2002-05-17 2003-11-20 Harland Ronald S. Rapidly disintegrating comressed tablets comprising biologically active compounds
WO2003103603A2 (en) 2002-06-10 2003-12-18 Wyeth Novel formate salt of o-desmethyl-venlafaxine
BR0312206A (pt) 2002-06-27 2005-04-12 Cilag Ag Formulações de pélete esférico
WO2004006921A1 (ja) 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
JP2005538105A (ja) 2002-07-25 2005-12-15 ファルマシア・コーポレーション 水不溶性ポリマーおよび水溶性の小孔形成物質からなる２層により被覆された固体剤形の製造方法
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
CA2415154C (en) 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
PT1781260E (pt) 2004-08-13 2010-12-20 Boehringer Ingelheim Int Formulação em comprimido de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável, um método para a preparação do mesmo e sua utilização
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
EP1886665A1 (en) * 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AR062321A1 (es) 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo

Also Published As

Publication number Publication date
HK1078007A1 (en) 2006-03-03
CA2493629C (en) 2013-10-08
TW200418465A (en) 2004-10-01
DE20321906U1 (de) 2012-11-07
ES2436745T3 (es) 2014-01-07
CN1671381B (zh) 2010-10-27
US20050175691A1 (en) 2005-08-11
US20140141079A1 (en) 2014-05-22
ES2421787T9 (es) 2013-11-06
DK1536792T3 (da) 2013-11-11
MA27372A1 (fr) 2005-06-01
KR20070062614A (ko) 2007-06-15
ES2421787T3 (es) 2013-09-05
KR101066374B1 (ko) 2011-09-20
CN1671381A (zh) 2005-09-21
CY1114566T1 (el) 2016-10-05
PL375444A1 (en) 2005-11-28
KR20050025654A (ko) 2005-03-14
EP1536792A1 (en) 2005-06-08
CA2493629A1 (en) 2004-02-05
RS52764B (en) 2013-10-31
AU2003256921A1 (en) 2004-02-16
EP1536792B1 (en) 2013-09-18
SG177011A1 (en) 2012-01-30
PT2289514E (pt) 2013-07-23
NZ562681A (en) 2009-11-27
IS7613A (is) 2004-12-23
DK2289514T3 (da) 2013-08-05
GEP20074047B (en) 2007-02-26
ECSP055569A (es) 2005-04-18
AU2003256921B2 (en) 2009-03-05
SI1536792T1 (sl) 2013-11-29
MXPA05000980A (es) 2005-09-12
EA200500080A1 (ru) 2005-06-30
ZA200500015B (en) 2006-07-26
OA12889A (en) 2006-10-13
EP2289514B1 (en) 2013-06-19
AP2223A (en) 2011-03-24
ME00347B (me) 2011-05-10
UY27913A1 (es) 2004-02-27
WO2004010999A1 (en) 2004-02-05
CU23468B7 (es) 2009-12-17
PT1536792E (pt) 2013-12-02
MY142204A (en) 2010-10-29
IL166076A0 (en) 2006-01-15
AP2005003206A0 (en) 2005-03-31
HRP20041234A2 (en) 2005-04-30
EP2289514B9 (en) 2013-08-21
NO20050481L (no) 2005-01-27
TWI351955B (en) 2011-11-11
MEP52208A (en) 2011-02-10
EP2289514A1 (en) 2011-03-02
JP4607584B2 (ja) 2011-01-05
PE20040134A1 (es) 2004-03-06
RS115104A (en) 2006-12-15
EA017595B1 (ru) 2013-01-30
BR0312948A (pt) 2005-06-14
HRP20041234B1 (hr) 2013-07-31
JP2005538995A (ja) 2005-12-22
SI2289514T1 (sl) 2013-08-30
CY1114263T1 (el) 2016-08-31
US8679533B2 (en) 2014-03-25
AR040682A1 (es) 2005-04-13
DK2289514T5 (da) 2013-09-30

Similar Documents

Publication Publication Date Title
PA8578501A1 (es) Forma de dosificacion una vez al dia de pramipexol
Findling et al. Original Research A Randomized Controlled Trial Investigating the Safety
ES2904526T3 (es) Pauta posológica de valbenazina para el tratamiento de discinesias hipercinéticas
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
PE20040121A1 (es) Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno
PE20110683A1 (es) Tratamiento de pirfenidona para pacientes con funcion hepatica atipica
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
PE20160195A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
NO20080244L (no) Doseringsstyring for prasugrel
HUP0202671A2 (hu) Ketotifen optikailag aktív izomerei és aktív metabolitjai
HN2003000112A (es) Comprimido masticable con sabor agradable
US20230125585A1 (en) Dosing protocols and regimens for aminosterol treatment
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
ES2610469T3 (es) Nuevas formulaciones farmacéuticas útiles en el tratamiento del insomnio
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
NO20061515L (no) Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
ES2312657T3 (es) Utilizacion de desoxipeganina en el tratamiento de la depresion clinica.
Godleski et al. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia
AR080292A1 (es) Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
TW200611697A (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
Aleberteau et al. Nitrous oxide reduced suicidal ideation in bipolar postpartum depression–A case report